^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

ROS1 fusion

i
Other names: ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, V-Ros Avian UR2 Sarcoma Virus Oncogene Homolog 1, C-Ros Oncogene 1 Receptor Tyrosine Kinase, Proto-Oncogene Tyrosine-Protein Kinase ROS, Proto-Oncogene C-Ros-1, MCF3, ROS, V-Ros UR2 Sarcoma Virus Oncogene Homolog 1 (Avian), ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, Transmembrane Tyrosine-Specific Protein Kinase, Receptor Tyrosine Kinase C-Ros Oncogene 1, C-Ros Receptor Tyrosine Kinase, Proto-oncogene C-Ros, C-Ros-1
Entrez ID:
Related tests:
2d
Mechanisms of Resistance to Tyrosine Kinase Inhibitors in ROS1 Fusion-Positive Nonsmall Cell Lung Cancer. (PubMed, Clin Chem)
This study provided a comprehensive portrait of TKI-resistance mechanisms in ROS1+ NSCLC patients. Using in silico simulations of TKI activity, novel secondary mutations that may confer TKI resistance were identified and may support clinical therapeutic decision-making.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD74 (CD74 Molecule) • SLC34A2 (Solute carrier family 34 member 2)
|
MET amplification • ROS1 fusion • ROS1 positive • ROS1 G2032R • ROS1 mutation
|
Xalkori (crizotinib) • Rozlytrek (entrectinib) • Lorbrena (lorlatinib)
2d
Enrollment open
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 fusion
7d
Kinase Fusions in Spitz Melanocytic Tumors: The Past, the Present, and the Future. (PubMed, Dermatopathology (Basel))
The knowledge of molecular drivers is of great interest in the field of melanocytic diagnostics, and it is important to consider that in addition to immunohistochemistry, molecular techniques such as FISH, PCR, and/or NGS are essential to confirm and classify the different patterns of mutation. Future studies with large case series and molecular sequencing techniques are needed to allow for a more complete and comprehensive understanding of the role of fusion kinases in the spitzoid tumor family.
Review • Journal
|
BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • NTRK (Neurotrophic receptor tyrosine kinase) • MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8)
|
ALK rearrangement • ALK fusion • ROS1 fusion • ROS1 rearrangement
7d
Trial primary completion date • Metastases
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
|
NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion
|
Rozlytrek (entrectinib)
9d
Efficacy of bevacizumab through an indwelling pleural catheter in non-small cell lung cancer patients with symptomatic malignant pleural effusion. (PubMed, BMC Pulm Med)
Bevacizumab through an IPC resulted in a significantly improved prognosis for NSCLC patients with MPE and actionable mutations. However, patients without actionable mutations do not benefit from bevacizumab through IPC.
Journal • Pleural effusion
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK fusion • ROS1 fusion • ALK-ROS1 fusion
|
Avastin (bevacizumab)
11d
Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase- and ROS1 Fusion-Positive Non-Small Cell Lung Cancer in India. (PubMed, JCO Glob Oncol)
Our study findings suggest that the prices of ceritinib and crizotinib need to be reduced significantly to justify their value for inclusion in India's publicly financed health insurance scheme for treatment of patients with locally advanced/metastatic ALK- and ROS1-positive NSCLC, respectively.
Journal • HEOR
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ALK positive • ROS1 fusion • ROS1 positive • ALK positive + ROS1 positive
|
Xalkori (crizotinib) • Zykadia (ceritinib)
15d
Trial initiation date
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 fusion • ROS1 positive
|
Rozlytrek (entrectinib)
15d
TRUST-II: Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (clinicaltrials.gov)
P2, N=224, Recruiting, AnHeart Therapeutics Inc. | N=154 --> 224
Enrollment change • Metastases
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 fusion
|
taletrectinib (AB-106)
17d
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial. (PubMed, ESMO Open)
Our final analysis proves the efficacy of crizotinib in ROS1-positive lung cancer, but also highlights the devastating impact of TP53 mutations on survival and treatment efficacy. Additionally, our data show that CNS disease control is durable and the risk of CNS progression while on crizotinib treatment is low.
Journal
|
TP53 (Tumor protein P53) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
TP53 mutation • ROS1 fusion • ROS1 positive • ROS1 rearrangement
|
Xalkori (crizotinib)
20d
Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer. (PubMed, Cancers (Basel))
These findings confirm crizotinib's sustained clinical efficacy and safety in a real-world context, which was characterized by a higher elderly population and higher rates of brain/CNS metastases. The study highlights the clinical relevance of liquid biopsy for detecting resistance mechanisms, suggesting its value in personalized treatment strategies.
Journal • Real-world evidence • Real-world • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD74 (CD74 Molecule)
|
KRAS mutation • KRAS G12D • ROS1 fusion • ROS1 rearrangement • KRAS G12 • ROS1 G2032R • ROS1 D2033N
|
Xalkori (crizotinib)
21d
Genomic Landscape of NSCLC in the Republic of Ireland. (PubMed, JTO Clin Res Rep)
Actionable alterations were identified in 53.4% of the patients, and KRAS was the most common oncogenic driver alteration. Our study revealed a lower prevalence of patients whose tumor harbors ALK, ROS1, and RET fusions, compared with similar data sets.
Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • FGFR3 (Fibroblast growth factor receptor 3) • NTRK (Neurotrophic receptor tyrosine kinase)
|
KRAS G12C • BRAF mutation • HER-2 amplification • MET amplification • RET fusion • MET exon 14 mutation • ROS1 fusion • KRAS G12A • KRAS G12 • FGFR3 fusion • BRAF G469A • NTRK fusion
1m
Repotrectinib: First Approval. (PubMed, Drugs)
In addition, preclinical investigation of repotrectinib in multiple myeloma is underway in the USA. This article summarizes the milestones in the development of repotrectinib leading to this first approval for the treatment of locally advanced or metastatic ROS1-positive NSCLC.
Review • Journal
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
|
ROS1 fusion • ROS1 positive
|
Augtyro (repotrectinib)
1m
Journal
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 fusion • ROS1 positive
|
Augtyro (repotrectinib)
1m
Translation into Clinical Practice of the G1-G7 Molecular Subgroup Classification of Glioblastoma: Comprehensive Demographic and Molecular Pathway Profiling. (PubMed, Cancers (Basel))
The correlations between the MAPK pathway G1-G7 subgroups and the PI3-kinase/PTEN, TERT, cell cycle G1 phase and p53 pathways defined characteristic subgroup pathway profiles amenable to personalized targeted therapy. This analysis validated the first all-inclusive molecular classification of glioblastoma, showed significant demographic and molecular differences between subgroups, and provided the first ethnic molecular comparison of glioblastoma.
Journal • Tumor mutational burden
|
EGFR (Epidermal growth factor receptor) • TMB (Tumor Mutational Burden) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NF1 (Neurofibromin 1) • LMNA (Lamin A/C) • PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)
|
EGFR mutation • NTRK1 fusion • NF1 mutation • ROS1 fusion • GOPC-ROS1 fusion • LMNA-NTRK1 fusion • NTRK1 overexpression
2ms
Taletrectinib for the treatment of ROS-1 positive non-small cell lung cancer: a drug evaluation of phase I and II data. (PubMed, Expert Opin Investig Drugs)
While crizotinib and entrectinib have been approved to treat ROS1 fusion-positive (ROS1+) non-small-cell lung cancer (NSCLC), unmet needs remain. Taltrectinib has the potential to improve PFS based on its greater potency against ROS1+ tumors and high CNS penetration. By selectively inhibiting ROS1 wild-type and its resistant mutations over TRKB, taltrectinib has a better safety profile with minimal CNS-related AEs compared to other ROS1+ inhibitors.
P1 data • Review • Journal
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
|
ROS1 fusion • ROS1 positive • ROS1 wild-type
|
Xalkori (crizotinib) • Rozlytrek (entrectinib) • taletrectinib (AB-106)
2ms
KEYNOTE KN-797: DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=115, Recruiting, Daiichi Sankyo, Inc. | Phase classification: P1b --> P1 | Trial primary completion date: Dec 2023 --> Feb 2024
Phase classification • Trial primary completion date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion • ALK-ROS1 fusion
|
Keytruda (pembrolizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
2ms
KLC1-ROS1 Fusion Exerts Oncogenic Properties of Glioma Cells via Specific Activation of JAK-STAT Pathway. (PubMed, Cancers (Basel))
Combination treatment with the chemotherapeutic agent temozolomide and an inhibitor of ROS1, JAK2, or a downstream target of STAT3, demonstrated antitumor effects against KLC1-ROS1 fusion-expressing glioma cells. Our results demonstrate that KLC1-ROS1 fusion exerts oncogenic activity through serum-independent constitutive activation, resulting in specific activation of the JAK-STAT pathway. Our data suggested that molecules other than RTKs may serve as novel therapeutic targets for RTK fusion in gliomas.
Journal
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • KLC1 (Kinesin light chain 1)
|
ROS1 fusion • ROS1 wild-type • KLC1-ROS1 fusion
|
temozolomide
2ms
Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience. (PubMed, Oncol Ther)
Optimized technical workflows are crucial in the decision-making strategy of patients with NSCLC. Artificial reference specimens enable optimization of diagnostic workflows for predictive molecular analysis in routine clinical practice.
Journal
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • KRAS G12C • MET exon 14 mutation • ROS1 fusion • KRAS G12 • KRAS exon 2 mutation • EGFR E746
2ms
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. (PubMed, N Engl J Med)
Repotrectinib had durable clinical activity in patients with ROS1 fusion-positive NSCLC, regardless of whether they had previously received a ROS1 TKI. Adverse events were mainly of low grade and compatible with long-term administration. (Funded by Turning Point Therapeutics, a wholly owned subsidiary of Bristol Myers Squibb; TRIDENT-1 ClinicalTrials.gov number, NCT03093116.).
Journal
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 fusion • ROS1 positive • ROS1 G2032R
|
Augtyro (repotrectinib)
2ms
Clinicopathological analysis of BRAF and non-BRAF MAPK pathway-altered gliomas in paediatric and adult patients: a single-institution study of 40 patients. (PubMed, J Clin Pathol)
The study provided insights into MAPK-altered gliomas in Kuwait highlighting the differences among paediatric and adult patients and providing a framework for planning therapeutic polices.
Journal
|
BRAF (B-raf proto-oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FGFR1 (Fibroblast growth factor receptor 1) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NF1 (Neurofibromin 1) • KIAA1549 • KANK1 (KN Motif And Ankyrin Repeat Domains 1) • TACC1 (Transforming Acidic Coiled-Coil Containing Protein 1)
|
BRAF V600E • NTRK2 fusion • NF1 mutation • ROS1 fusion • KIAA1549-BRAF fusion • BRAF fusion • FGFR1 fusion • BRAF amplification
2ms
Exploring the Clinical Utility of Molecular Profiling of Intrahepatic Cholangiocarcinoma in a Comprehensive Multidisciplinary Clinic. (PubMed, J Am Coll Surg)
Actionable molecular alterations were frequently observed in patients with ICC. Detection of actionable alterations was associated with improved OS. The role of targeted therapy needs further exploration in prospective multi-center studies.
Journal • Tumor mutational burden • BRCA Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
BRAF V600E • BRCA2 mutation • BRCA1 mutation • TMB-H • HER-2 overexpression • HER-2 amplification • PIK3CA mutation • BRAF V600 • MET amplification • FGFR2 mutation • FGFR2 fusion • ROS1 fusion • MET mutation • FGFR3 amplification
2ms
APG-2449 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=150, Recruiting, Ascentage Pharma Group Inc.
Trial completion date • Trial primary completion date • Metastases
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ALK positive • ROS1 fusion • ROS1 positive • ALK-ROS1 fusion
|
APG-2449
2ms
Combination therapy • Trial completion date • Trial primary completion date • Metastases
|
RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
RET fusion • ALK fusion • ROS1 fusion
|
VENTANA ALK (D5F3) CDx Assay
|
Rybrevant (amivantamab-vmjw)
2ms
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion
|
temozolomide • irinotecan • Augtyro (repotrectinib)
2ms
Trial completion date • Metastases
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ROS1 fusion
|
patritumab deruxtecan (U3-1402)
2ms
Abdominal inflammatory myofibroblastic tumour: Clinicopathological and molecular analysis of 20 cases, highlighting potential therapeutic targets. (PubMed, Histopathology)
This study shows the wide clinical spectrum of abdominal IMTs and affirms the poor prognosis of EIMS, raising discussion about its status as IMT subtype. Furthermore, the newly detected alterations of the RTK/PI3K/AKT pathway expand the molecular landscape of IMTs and provide potential therapeutic targets.
Journal
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • RANBP2 (RAN Binding Protein 2)
|
ALK fusion • ROS1 fusion • ALK translocation • ALK-ROS1 fusion
2ms
The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC. (clinicaltrials.gov)
P1; Trial completion date: Nov 2023 --> Dec 2025 | Trial primary completion date: Aug 2023 --> Dec 2024
Trial completion date • Trial primary completion date • Metastases
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
PD-L1 expression • EGFR T790M • PD-L1 negative • ALK fusion • ROS1 fusion • ALK-ROS1 fusion
|
PD-L1 IHC 22C3 pharmDx
|
Lenvima (lenvatinib) • reozalimab (IBI318)
2ms
CD74-ROS1 L2026M mutant enhances autophagy through the MEK/ERK pathway to promote invasion, metastasis and crizotinib resistance in non-small cell lung cancer cells. (PubMed, FEBS J)
In addition, the L2026M mutation led to excessive activation of the MEK/ERK pathway, and MEK inhibitors could reduce the autophagy level, invasion and metastasis abilities of cells; additionally, this process could be blocked by rapamycin, an activator of autophagy. Furthermore, crizotinib treatment activated expression of Src homology region 2 domain-containing phosphatase-2 (SHP2; also known as PTPN11) to upregulate the MEK/ERK pathway, and the combination of MEK inhibitors and crizotinib increased apoptosis compared with crizotinib alone. In conclusion, our results indicate that the MEK/ERK pathway mediates the induction of invasion, metastasis and crizotinib resistance through autophagy caused by CD74-ROS1 L2026M mutation in NSCLC cells, and targeting MEK could reverse these processes.
Journal
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD74 (CD74 Molecule) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1)
|
ROS1 fusion
|
Xalkori (crizotinib) • sirolimus
2ms
Case report: Successful sequential therapy of crizotinb and entrectinib in ROS1-positive non-small-cell lung cancer with brain metastasis in later-settings. (PubMed, Medicine (Baltimore))
A ROS1-rearranged NSCLC with CNS metastases responded to sequential tyrosine kinase inhibitors treatment of crizotinb followed by entrectinib. This report has potential implications in guiding decisions for the treatment after crizotinib resistance.
Journal • PD(L)-1 Biomarker
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
|
NTRK2 fusion • ALK fusion • ALK mutation • ROS1 fusion • ROS1 positive • ROS1 rearrangement
|
Opdivo (nivolumab) • Avastin (bevacizumab) • Xalkori (crizotinib) • Rozlytrek (entrectinib) • paclitaxel • Focus V (anlotinib)
3ms
Different effects of crizotinib treatment in two non-small cell lung cancer patients with SDC4::ROS1 fusion variants. (PubMed, Thorac Cancer)
The Ki67 index was not different, but ROS1 and pERK1/2 expression levels tended to be higher in the tumor cells of case 2 than in case 1. Therapeutic response to crizotinib and patients' prognosis in ROS1 rearranged NSCLC may be related to the activation of ROS1 signaling, depending on ROS1 and pERK1/2 overexpression status, even if the ROS1 fusion partner is the same.
Journal
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • SDC4 (Syndecan 4)
|
ROS1 fusion • ROS1 positive • ROS1 rearrangement • SDC4-ROS1 fusion
|
Xalkori (crizotinib)
3ms
Comprehensive review of ROS1 tyrosine kinase inhibitors (TKIs)-classified by structural designs and mutation spectrum [solvent front mutation (G2032R) and central β-sheet 6 (Cβ6) mutation (L2086F)]. (PubMed, J Thorac Oncol)
Despite ROS1 fusion positive (ROS1+) NSCLC accounting approximately 1-2% of NSCLC, there is a dizzying list of ROS1 tyrosine kinase inhibitor (TKIs) being developed in addition to two approved ROS1 TKIs, crizotinib and entrectinib...Additionally, the less known central β-sheet 6 (Cβ6) mutation ROS1 L2086F confer resistances to next-generation ROS1 TKIs (taletrectinib, lorlatinib, potentially NVL-520) that can be overcome by cabozantinib as documented in published patient reports and may potentially by certain L-shaped Type I ROS1 TKIs including gilteritinib which is approved as a FLT3 inhibitor for AML. Future clinical trials should investigate cabozantinib and gilteritinib to repurpose them as ROS1 TKIs that can target Cβ6 mutation.
Review • Journal
|
FLT3 (Fms-related tyrosine kinase 3) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 fusion • ROS1 positive • ROS1 G2032R • ROS1 L2086F
|
Xalkori (crizotinib) • Rozlytrek (entrectinib) • Lorbrena (lorlatinib) • Xospata (gilteritinib) • Cabometyx (cabozantinib tablet) • Augtyro (repotrectinib) • taletrectinib (AB-106) • NVL-520
3ms
CD74/SLC34A2-ROS1 fusion variants involving the transmembrane region predict poor response to crizotinib in non-small cell lung cancer independent of TP53 mutations. (PubMed, J Thorac Oncol)
Long CD74/SLC34A2-ROS1 fusions, which retain transmembrane regions in ROS1 and fusion partners, are associated with poor response to crizotinib independent of TP53 mutations.
Journal
|
TP53 (Tumor protein P53) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD74 (CD74 Molecule) • SLC34A2 (Solute carrier family 34 member 2) • TPM3 (Tropomyosin 3) • SDC4 (Syndecan 4)
|
TP53 mutation • ROS1 fusion • ROS1 rearrangement • SDC4-ROS1 fusion • BCL2L11 deletion • SLC34A2-ROS1 fusion
|
Xalkori (crizotinib)
3ms
Genetic Alterations and Risk Factors for Recurrence in Patients with Non-Small Cell Lung Cancer Who Underwent Complete Surgical Resection. (PubMed, Cancers (Basel))
In conclusion, adjuvant or neoadjuvant targeted therapy could be considered more actively because EGFR mutations were identified as an independent risk factor for recurrence and were associated with systemic recurrence. Further studies on perioperative therapy for other genetic alterations are necessary.
Journal
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ALK rearrangement • ROS1 fusion
3ms
Trial completion date
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • gemcitabine • docetaxel • Cyramza (ramucirumab) • pemetrexed
3ms
Trial completion date
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset) • CD4 (CD4 Molecule)
|
BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • EGFR T790M • HRD • ALK fusion • ROS1 fusion • HRD + BRCA1 mutation
|
Rubraca (rucaparib)
3ms
Genomics and transcriptomics of pancreatic adenosquamous carcinoma. (ASCO-GI 2024)
This is the largest molecular profiling analysis of PASC, which is characterized by unique genomic alterations, and is associated with higher PD-L1 expression, immune related gene expression, CD4+ T cell infiltration and IFN gamma signature, and lower MAPK activation. PASC is associated with better OS compared to PSCC. These findings may provide subtype-specific therapeutic opportunities for PASC and PSCC pts.
PD(L)-1 Biomarker • MSi-H Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • SF3B1 (Splicing Factor 3b Subunit 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD4 (CD4 Molecule) • AKT2 (V-akt murine thymoma viral oncogene homolog 2) • CASP8 (Caspase 8) • HMGA2 (High mobility group AT-hook 2) • AXIN1 (Axin 1) • CDKN1B (Cyclin dependent kinase inhibitor 1B) • BCL9 (BCL9 Transcription Coactivator) • ZNF384 (Zinc Finger Protein 384)
|
PD-L1 expression • TMB-H • MSI-H/dMMR • PTEN mutation • ROS1 fusion • SF3B1 mutation • CTLA4 expression • AKT2 amplification • CD4 expression
|
MI Tumor Seek™
3ms
New P4 trial
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK positive • ALK fusion • ROS1 fusion • ROS1 positive • ALK-ROS1 fusion
|
Navelbine oral (vinorelbine tartrate oral)
3ms
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • NTRK (Neurotrophic receptor tyrosine kinase)
|
KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • HLA-A*11 • NTRK fusion
|
cyclophosphamide • bendamustine • fludarabine IV
3ms
Relationship between driver gene mutations and clinical pathological characteristics in older lung adenocarcinoma. (PubMed, Front Oncol)
Older LUAD populations exhibit diverse genetic mutations, which may also exist simultaneously. Simultaneous detection of multiple genes by NGS can accelerate and enhance targeted treatment benefits for older LUAD patients, ultimately improving their quality of life.
Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • PKHD1 (PKHD1 Ciliary IPT Domain Containing Fibrocystin/Polyductin)
|
KRAS mutation • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • RET fusion • ROS1 fusion
3ms
Clinical • P1/2 data
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 fusion • ROS1 positive
|
Augtyro (repotrectinib)
3ms
Enrollment change
|
BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD8 (cluster of differentiation 8) • CDH1 (Cadherin 1) • CD14 (CD14 Molecule) • VIM (Vimentin) • MRC1 (Mannose Receptor C-Type 1)
|
BRAF V600E • EGFR mutation • BRAF V600 • EGFR L858R • ROS1 fusion
3ms
A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=160, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Aug 2025 --> Nov 2025 | Initiation date: Aug 2023 --> Oct 2023 | Trial primary completion date: Aug 2025 --> Nov 2025
Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
BRAF mutation • BRAF V600 • EGFR wild-type • MET exon 14 mutation • ALK fusion • RET mutation • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion
|
izalontamab (SI-B001) • SI-B003